HSV-1 gC Envelope Protein Antibody (3G9): sc-56982

HSV-1 gC Envelope Protein Antibody (3G9) is a mouse monoclonal IgG2a antibody that detects the glycoprotein C envelope protein of Herpes simplex virus 1 by western blotting (WB) and immunofluorescence (IF). HSV-1 gC Envelope Protein (3G9) antibody is available as the non-conjugated anti-HSV-1 gC Envelope Protein antibody. Herpes simplex virus 1 (HSV-1) is a member of the Herpesviridae family, characterized by its large double-stranded linear DNA genome encased in an icosahedral capsid and surrounded by a lipid bilayer envelope. The glycoprotein C (gC) plays a crucial role in the virus′s ability to evade the host immune response; gC binds to the complement component C3b, effectively inhibiting complement-mediated neutralization and allowing HSV-1 to persist in the host. This immune evasion is particularly important as gC enables HSV-1 to establish latency in nerve cells, where HSV-1 can remain dormant and reactivate later, leading to recurrent infections. HSV-1 gC enhances coagulation Factor VIIa activity, which further underscores gC′s significance in the viral life cycle, as Factor X activation promotes viral spread and pathogenesis. Understanding HSV-1 gC function is vital for developing therapeutic strategies against HSV-1 infections, making anti-HSV-1 gC Envelope Protein antibody (3G9) an essential tool for researchers studying this virus.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-1 gC Envelope Protein Antibody (3G9) References:

1. Monoclonal antibodies suitable for type-specific identification of herpes simplex viruses by a rapid culture assay.  |  Bystrická, M., et al. 1999. Acta Virol. 43: 399-402. PMID: 10825932
2. Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus.  |  Sutherland, MR., et al. 2004. Thromb Haemost. 92: 947-55. PMID: 15543320
3. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway.  |  Gregory, D., et al. 2004. J Virol. 78: 13582-90. PMID: 15564469
4. Production of herpes B virus recombinant glycoproteins and evaluation of their diagnostic potential.  |  Perelygina, L., et al. 2005. J Clin Microbiol. 43: 620-8. PMID: 15695655
5. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.  |  Chang, YJ., et al. 2005. Vaccine. 23: 4658-65. PMID: 15936852
6. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.  |  Hook, LM., et al. 2006. J Virol. 80: 4038-46. PMID: 16571820
7. Type-common and type-specific monoclonal antibodies to herpes simplex virus types 1 and 2.  |  Bystrická, M., et al. 1991. Acta Virol. 35: 152-64. PMID: 1681713
8. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.  |  Bröker, M., et al. 1990. Med Microbiol Immunol. 179: 145-59. PMID: 2169577
9. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.  |  Egan, KP., et al. 2020. PLoS Pathog. 16: e1008795. PMID: 32716975
10. Enhancement of HSV-1 cell-free virion release by the envelope protein gC.  |  Frost, TC., et al. 2024. Virology. 596: 110120. PMID: 38805801
11. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.  |  Bystrická, M., et al. 1997. Acta Virol. 41: 5-12. PMID: 9199708
12. Herpes simplex virus type 1-encoded glycoprotein C contributes to direct coagulation factor X-virus binding.  |  Livingston, JR., et al. 2006. Biochem J. 393: 529-35. PMID: 16212554